Lenvima(lenvatinib)
Kisplyx, Lenvima (lenvatinib) is a small molecule pharmaceutical. Lenvatinib was first approved as Lenvima on 2015-02-13. It is used to treat renal cell carcinoma and thyroid neoplasms in the USA. It has been approved in Europe to treat renal cell carcinoma and thyroid neoplasms. The pharmaceutical is active against vascular endothelial growth factor receptor 3 and vascular endothelial growth factor receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Lenvima
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lenvima | New Drug Application | 2024-06-11 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| renal cell carcinoma | EFO_0000376 | D002292 | — |
| thyroid neoplasms | EFO_0003841 | D013964 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LENVATINIB MESYLATE, LENVIMA, EISAI INC | |||
| 2025-08-15 | ODE-196 | ||
| 2024-12-19 | M-272 | ||
| 2024-08-10 | I-868 | ||
| 2024-07-21 | M-269 | ||
HCPCS
No data
Clinical
Clinical Trials
515 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 46 | 126 | 42 | 4 | 50 | 241 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 31 | 100 | 37 | 4 | 52 | 201 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 25 | 85 | 31 | 2 | 45 | 168 |
| Neoplasms | D009369 | — | C80 | 26 | 31 | 3 | 1 | 4 | 54 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 15 | 26 | 5 | 1 | 4 | 44 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 3 | 19 | 2 | 3 | 7 | 32 |
| Cholangiocarcinoma | D018281 | — | C22.1 | 1 | 20 | 3 | 1 | 5 | 28 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | 17 | 2 | 2 | 5 | 26 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 4 | 11 | 4 | 1 | 3 | 22 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 3 | 11 | — | 1 | — | 15 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 6 | 17 | 4 | — | 8 | 32 |
| Melanoma | D008545 | — | — | 8 | 18 | 2 | — | 1 | 22 |
| Non-small-cell lung carcinoma | D002289 | — | — | 5 | 12 | 6 | — | — | 19 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 12 | 6 | — | 1 | 19 |
| Adenocarcinoma | D000230 | — | — | 5 | 8 | 1 | — | 1 | 14 |
| Esophageal neoplasms | D004938 | — | C15 | 3 | 7 | 1 | — | — | 9 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 3 | 5 | 2 | — | — | 8 |
| Squamous cell carcinoma | D002294 | — | — | 3 | 5 | 2 | — | — | 8 |
| Colorectal neoplasms | D015179 | — | — | 4 | 5 | 1 | — | — | 7 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | 4 | 1 | — | — | 6 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biliary tract neoplasms | D001661 | — | C24.9 | 1 | 21 | — | — | 1 | 22 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 7 | — | — | — | 8 |
| Small cell lung carcinoma | D055752 | — | — | 2 | 6 | — | — | 1 | 7 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 6 | — | — | — | 6 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 3 | 5 | — | — | — | 6 |
| Anaplastic thyroid carcinoma | D065646 | — | — | — | 6 | — | — | — | 6 |
| Triple negative breast neoplasms | D064726 | — | — | 3 | 5 | — | — | — | 6 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 4 | — | — | — | 5 |
| Sarcoma | D012509 | — | — | 2 | 5 | — | — | — | 5 |
| Immunotherapy | D007167 | — | — | — | 1 | — | — | 4 | 5 |
Show 75 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 4 | — | — | — | — | 4 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | 3 | 4 |
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 2 | — | — | — | — | 2 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
Show 31 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Catheter ablation | D017115 | — | — | — | — | — | — | 2 | 2 |
| Medullary carcinoma | D018276 | — | — | — | — | — | — | 1 | 1 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | — | — | 1 | 1 |
| Digestive system neoplasms | D004067 | — | — | — | — | — | — | 1 | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 1 | 1 |
| Progression-free survival | D000077982 | — | — | — | — | — | — | 1 | 1 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | — | — | — | 1 | 1 |
| Hepatic encephalopathy | D006501 | — | K72.91 | — | — | — | — | 1 | 1 |
| Radiofrequency ablation | D000078703 | — | — | — | — | — | — | 1 | 1 |
| Apoptosis | D017209 | — | — | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lenvatinib |
| INN | lenvatinib |
| Description | Lenvatinib is a member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine. It has a role as a vascular endothelial growth factor receptor antagonist, an orphan drug, an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and a fibroblast growth factor receptor antagonist. It is a member of quinolines, an aromatic ether, a monocarboxylic acid amide, an aromatic amide, a member of monochlorobenzenes, a member of cyclopropanes and a member of phenylureas. It is a conjugate base of a lenvatinib(1+). |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 417716-92-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1289601 |
| ChEBI ID | 85994 |
| PubChem CID | 9823820 |
| DrugBank | DB09078 |
| UNII ID | EE083865G2 (ChemIDplus, GSRS) |
Target
Agency Approved
FLT4
FLT4
KDR
KDR
Organism
Homo sapiens
Gene name
FLT4
Gene synonyms
VEGFR3
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 3
Protein synonyms
Feline McDonough Sarcoma (FMS)-like tyrosine kinase 4, FLT-4, fms related tyrosine kinase 4, Fms-like tyrosine kinase 4, primary congenital lymphedema, Tyrosine-protein kinase receptor FLT4, VEGF receptor-3
Uniprot ID
Mouse ortholog
Flt4 (14257)
vascular endothelial growth factor receptor 3 (P35917)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Lenvima – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,215 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
27,180 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use